Inhibition of DPP-4 by alogliptin improves coronary flow reserve and left ventricular systolic function evaluated by phase contrast cine magnetic resonance imaging in patients with type 2 diabetes and coronary artery disease
| Autor: | Tae Iwasawa, Daiki Gyotoku, Tatsuya Nakachi, Shingo Kato, Kazuki Fukui, Hidekuni Kirigaya, Kazuo Kimura, Naoki Iinuma, Kohei Iguchi, Yuka Kusakawa |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Diet therapy Dipeptidyl Peptidase 4 Magnetic Resonance Imaging Cine Type 2 diabetes Coronary Artery Disease 030204 cardiovascular system & hematology Ventricular Function Left 030218 nuclear medicine & medical imaging Coronary artery disease Cohort Studies 03 medical and health sciences 0302 clinical medicine Piperidines Internal medicine medicine Humans Prospective Studies Uracil Coronary sinus Aged Aged 80 and over Dipeptidyl-Peptidase IV Inhibitors Ejection fraction business.industry Coronary flow reserve Blood flow medicine.disease Fractional Flow Reserve Myocardial Endocrinology Diabetes Mellitus Type 2 Cardiology Female Cardiology and Cardiovascular Medicine business Alogliptin |
| Zdroj: | International journal of cardiology. 223 |
| ISSN: | 1874-1754 |
| Popis: | Background The present study determined whether dipeptidyl peptidase-4 (DPP-4) inhibition by alogliptin improves coronary flow reserve (CFR) and left ventricular election fraction (LVEF) in patients with type 2 DM and CAD. Materials and methods Twenty patients with type 2 DM and known or suspected CAD were randomly allocated to receive diet therapy plus alogliptin (n=10; mean age, 73.3±6.6y) or a control group given diet therapy and glimepiride (n=10; mean age, 76.7±7.3y). Breath-hold PC cine MR images of the coronary sinus (CS) were acquired using a 1.5T MR scanner and 32 channel cardiac coils to assess blood flow of the CS at rest and during adenosine triphosphate (ATP) infusion. The CFR was calculated as CS blood flow during ATP infusion divided by that at rest. The CFR and LVEF were evaluated by MRI at baseline and at three months after starting therapy. Results Hemoglobin A1c (HbA1c) was significantly reduced in both groups (alogliptin, 7.2±0.6% to 6.6±0.5%, p=0.034; control, 6.9±0.4% to 6.4±0.3%, p=0.008). However, CFR and LVEF significantly improved only in the alogliptin group (alogliptin: CFR, 2.15±0.61 to 2.85±0.80, p=0.042; LVEF, 59.4±6.3% to 68.0±8.6%, p=0.03; control: CFR, 2.17±0.37 to 2.38±0.32, p=0.19; LVEF, 58.2±9.1 to 60.3±8.8%, p=0.61). The % increases in CFR and in LVEF positively correlated (R=0.47 by Spearman's correlation coefficient; p=0.036). Conclusion The inhibition of DPP-4 by alogliptin improved CFR and LVEF evaluated by MRI in patients with type 2 DM and CAD and the improvement in CFR was associated with increased LV systolic function. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect